Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Dec 28 2021

Filgrastim / Sargramostim

  • Snapshot
    • A 55-year-old man with non-Hodgkin lymphoma undergoing chemotherapy is about to get his first dose of filgrastim, a granulocyte-colony stimulating factor, for his chemotherapy-induced neutropenia. A few minutes after the dose, he starts feeling pruritus, and it was noted by the nurse that he developed urticaria over his trunk. He did not experience swelling of his lips, tongue, or throat. He is given a dose of diphenhydramine and monitored for the next few hours. His urticaria subsides, and he continues to deny any difficulty breathing or throat swelling.
  • Introduction
    • Drugs
      • filgrastim
        • recombinant human granulocyte-colony stimulating factor (G-CSF)
      • pegfilgrastim
        • recombinant PEG-conjugated human G-CSF
      • sargramostim
        • recombinant granulocyte macrophage CSF (GM-CSF)
    • Mechanism of action
      • G-CSF
        • stimulates production of neutrophils
      • GM-CSF
        • stimulates production of neutrophils, dendritic cells, and monocytes/macrophages
    • Clinical use
      • neutropenia
        • myelosuppressive chemotherapy
        • aplastic anemia
        • congenital neutropenia
      • stem cell transplantation
    • Adverse effects
      • nausea and vomiting
      • bone pain
      • cutaneous vasculitis
      • allergic reaction
        • angioedema
        • urticaria
        • anaphylaxis
      • thrombocytopenia
      • capillary leak syndrome
      • leukocytosis
Card
1 of 0
Private Note